KR20240110106A - Il-17a-결합 폴리펩티드 - Google Patents
Il-17a-결합 폴리펩티드 Download PDFInfo
- Publication number
- KR20240110106A KR20240110106A KR1020247022438A KR20247022438A KR20240110106A KR 20240110106 A KR20240110106 A KR 20240110106A KR 1020247022438 A KR1020247022438 A KR 1020247022438A KR 20247022438 A KR20247022438 A KR 20247022438A KR 20240110106 A KR20240110106 A KR 20240110106A
- Authority
- KR
- South Korea
- Prior art keywords
- binding
- sequence
- seq
- binding polypeptide
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- Obesity (AREA)
- Neurology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15150786.0 | 2015-01-12 | ||
| EP15150786 | 2015-01-12 | ||
| PCT/EP2016/050456 WO2016113246A1 (en) | 2015-01-12 | 2016-01-12 | Il-17a-binding polypeptides |
| KR1020177021726A KR102683288B1 (ko) | 2015-01-12 | 2016-01-12 | Il-17a-결합 폴리펩티드 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177021726A Division KR102683288B1 (ko) | 2015-01-12 | 2016-01-12 | Il-17a-결합 폴리펩티드 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240110106A true KR20240110106A (ko) | 2024-07-12 |
Family
ID=52339024
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247022438A Pending KR20240110106A (ko) | 2015-01-12 | 2016-01-12 | Il-17a-결합 폴리펩티드 |
| KR1020177021726A Active KR102683288B1 (ko) | 2015-01-12 | 2016-01-12 | Il-17a-결합 폴리펩티드 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177021726A Active KR102683288B1 (ko) | 2015-01-12 | 2016-01-12 | Il-17a-결합 폴리펩티드 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10934335B2 (https=) |
| EP (3) | EP3738976B1 (https=) |
| JP (3) | JP6943764B2 (https=) |
| KR (2) | KR20240110106A (https=) |
| CN (1) | CN108064235A (https=) |
| AU (1) | AU2016208161B2 (https=) |
| CA (1) | CA2972683A1 (https=) |
| DK (1) | DK3245224T3 (https=) |
| ES (1) | ES2822431T3 (https=) |
| HU (1) | HUE052121T2 (https=) |
| IL (1) | IL253004B (https=) |
| MX (1) | MX394167B (https=) |
| MY (1) | MY188784A (https=) |
| NZ (1) | NZ732978A (https=) |
| PL (1) | PL3245224T3 (https=) |
| PT (1) | PT3245224T (https=) |
| RU (1) | RU2749712C2 (https=) |
| WO (1) | WO2016113246A1 (https=) |
| ZA (1) | ZA201704366B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY37651A (es) * | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
| CN108949789A (zh) * | 2018-06-26 | 2018-12-07 | 山东兴瑞生物科技有限公司 | 抗gcc的核酸、其制备方法、具有该核酸的免疫细胞及其应用 |
| JP7525499B2 (ja) * | 2019-01-31 | 2024-07-30 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法 |
| US20220389066A1 (en) * | 2019-11-05 | 2022-12-08 | Affibody Ab | Polypeptides |
| CN111856029B (zh) * | 2020-06-19 | 2023-09-26 | 北华大学 | Il-17a蛋白在膀胱癌中的应用 |
| EP4476247A1 (en) * | 2022-02-08 | 2024-12-18 | Affibody AB | Protein z variants binding thymic stromal lymphopoietin and their medical use |
| WO2023196916A1 (en) * | 2022-04-07 | 2023-10-12 | Acelyrin, Inc. | Methods of treating of hidradenitis suppurativa |
| US20260028397A1 (en) | 2022-04-07 | 2026-01-29 | Acelyrin, Inc. | Methods of treating ankylosing spondylitis |
| WO2024227930A1 (en) * | 2023-05-04 | 2024-11-07 | Affibody Ab | New polypeptide |
| CN116466095B (zh) * | 2023-06-15 | 2023-09-01 | 朗肽生物制药股份有限公司 | 一种多肽及其应用 |
| WO2025054498A1 (en) * | 2023-09-08 | 2025-03-13 | Acelyrin, Inc. | Methods of treating hidradenitis suppurativa |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0524788D0 (en) * | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| CN101326195B9 (zh) | 2005-12-13 | 2022-11-11 | 伊莱利利公司 | 抗il-17抗体 |
| CA2675137A1 (en) | 2007-01-12 | 2008-07-24 | Sea Lane Biotechnologies, Llc. | Combinatorial libraries of conformationally constrained polypeptide sequences |
| CA2694139C (en) | 2007-07-31 | 2018-06-05 | Affibody Ab | Albumin binding polypeptide compositions |
| DK2231860T3 (da) | 2007-12-19 | 2011-12-05 | Affibody Ab | Polypeptid afledt protein A og i stand til at binde PDGF |
| EP2403531A4 (en) * | 2009-03-05 | 2013-02-27 | Abbott Lab | IL-17 BINDING PROTEINS |
| MX2012002428A (es) | 2009-08-27 | 2012-09-12 | Covagen Ag | Compuestos de union il-17 y usos medicos de los mismos. |
| CN102811782A (zh) | 2010-03-08 | 2012-12-05 | 通用电气健康护理生物科学股份公司 | 免疫球蛋白G Fc区结合多肽 |
| MX2013000314A (es) | 2010-07-09 | 2013-01-29 | Affibody Ab | Polipeptidos. |
| WO2012125680A1 (en) | 2011-03-16 | 2012-09-20 | Novartis Ag | Methods of treating vasculitis using an il-17 binding molecule |
| EP2597102A1 (en) | 2011-11-25 | 2013-05-29 | Covagen AG | A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17 |
| WO2013126006A1 (en) * | 2012-02-20 | 2013-08-29 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement c5 |
| EP2711016A1 (en) | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
| CN111763247B (zh) | 2012-09-25 | 2024-09-13 | 阿菲博迪公司 | 白蛋白结合多肽 |
| AU2013336646B2 (en) * | 2012-10-25 | 2016-07-14 | Affibody Ab | ABD binding polypeptide |
| WO2014113804A1 (en) * | 2013-01-21 | 2014-07-24 | Abbvie Inc. | Anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease |
| ES2660912T3 (es) * | 2013-03-15 | 2018-03-26 | Affibody Ab | Nuevos polipéptidos |
| WO2015091957A1 (en) | 2013-12-20 | 2015-06-25 | Affibody Ab | Engineered albumin binding polypeptide |
-
2016
- 2016-01-12 CN CN201680011379.3A patent/CN108064235A/zh active Pending
- 2016-01-12 MX MX2017008660A patent/MX394167B/es unknown
- 2016-01-12 EP EP20180610.6A patent/EP3738976B1/en active Active
- 2016-01-12 KR KR1020247022438A patent/KR20240110106A/ko active Pending
- 2016-01-12 HU HUE16700424A patent/HUE052121T2/hu unknown
- 2016-01-12 PT PT167004241T patent/PT3245224T/pt unknown
- 2016-01-12 CA CA2972683A patent/CA2972683A1/en active Pending
- 2016-01-12 ES ES16700424T patent/ES2822431T3/es active Active
- 2016-01-12 US US15/538,890 patent/US10934335B2/en active Active
- 2016-01-12 EP EP25184869.3A patent/EP4643955A3/en active Pending
- 2016-01-12 MY MYPI2017702236A patent/MY188784A/en unknown
- 2016-01-12 PL PL16700424T patent/PL3245224T3/pl unknown
- 2016-01-12 WO PCT/EP2016/050456 patent/WO2016113246A1/en not_active Ceased
- 2016-01-12 DK DK16700424.1T patent/DK3245224T3/da active
- 2016-01-12 KR KR1020177021726A patent/KR102683288B1/ko active Active
- 2016-01-12 JP JP2017535976A patent/JP6943764B2/ja active Active
- 2016-01-12 NZ NZ732978A patent/NZ732978A/en unknown
- 2016-01-12 EP EP16700424.1A patent/EP3245224B1/en active Active
- 2016-01-12 RU RU2017127012A patent/RU2749712C2/ru active
- 2016-01-12 AU AU2016208161A patent/AU2016208161B2/en active Active
-
2017
- 2017-06-19 IL IL253004A patent/IL253004B/en active IP Right Grant
- 2017-06-27 ZA ZA2017/04366A patent/ZA201704366B/en unknown
-
2020
- 2020-12-17 JP JP2020209139A patent/JP7208963B2/ja active Active
-
2021
- 2021-02-01 US US17/163,961 patent/US12221464B2/en active Active
-
2023
- 2023-01-06 JP JP2023001177A patent/JP7456024B2/ja active Active
-
2024
- 2024-07-31 US US18/790,379 patent/US20250101074A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7456024B2 (ja) | Ｉｌ－１７ａ結合ポリペプチド | |
| JP2019503167A (ja) | Ｃｄ３８に対する抗原結合性ポリペプチド | |
| TW201726731A (zh) | 對TNF-α、IL-17A及IL-17F具特異性之多重特異性抗體分子 | |
| JP2023175822A (ja) | 特異的結合分子 | |
| KR101787003B1 (ko) | 신규한 폴리펩티드 | |
| EP3154563B1 (en) | New polypeptide | |
| HK40034041A (en) | Il-17a-binding fusion protein | |
| HK1238661A1 (en) | Il-17a-binding polypeptides | |
| HK1238661B (en) | Il-17a-binding polypeptides | |
| HK40034041B (en) | Il-17a-binding fusion protein | |
| BR122024013519A2 (pt) | Polipeptídeo de ligação de il-17a, proteína de fusão ou conjugado, complexo, polinucleotídeo que codifica um polipeptídeo, e, composição | |
| BR112017014559B1 (pt) | Proteína de fusão compreendendo dois polipeptídeos de ligação a il- 17a e composição | |
| HK1235302B (en) | New polypeptide | |
| HK1235302A1 (en) | New polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |